Adnan Alsumali1, Dominik Lautsch2, Rongzhe Liu3, Dipen Patel3, Sakina Nanji3, Laurence M Djatche2. 1. Center for Observational and Real-World Evidence, Merck & Co, Inc, Kenilworth, NJ, USA. adnan.alsumali@merck.com. 2. Center for Observational and Real-World Evidence, Merck & Co, Inc, Kenilworth, NJ, USA. 3. Pharmerit - an OPEN Health Company, Bethesda, MD, USA.
Abstract
INTRODUCTION: In the USA, patients with chronic heart failure (HF) with reduced ejection fraction (HFrEF) following a worsening HF event (WHFE) have significantly increased healthcare resource use and medical costs. This analysis aimed to estimate the budget impact of vericiguat as an add-on therapy to guideline-directed medical therapy (GDMT) for the treatment of chronic HFrEF following a WHFE from a US commercial payer perspective. METHODS: A model was developed to estimate the budget impact of adding vericiguat to the formulary by comparing a current scenario (GDMT) and a new scenario (vericiguat plus GDMT) to a hypothetical 10-million-member commercial payer over a 3-year time horizon. Epidemiology data was obtained from literature. Treatment utilization rates of GDMT and clinical inputs (HF hospitalization and cardiovascular [CV] morality) were based on the VICTORIA trial in which patients with chronic HFrEF following a WHFE were randomized to GDMT plus placebo or GDMT plus vericiguat. Costs (2020 US$) included drug acquisition, hospitalization, routine care, and mortality. RESULTS: Approximately 20,510 prevalent cases in year 1 and 3109 annual incident cases in subsequent years were estimated to be eligible for treatment with vericiguat. At a utilization rate of 5%, 10%, and 15% for vericiguat over years 1-3, the per member per month (PMPM) budget impact was estimated to be $0.048, $0.064, and $0.086, respectively, associated with 44, 32, and 30 fewer HF hospitalizations and 7, 12, and 18 fewer CV deaths, respectively. Reduction in HF hospitalizations and CV deaths reduced the budget impact by 14% in total over 3 years. CONCLUSION: Adding vericiguat to commercial plan formulary was associated with limited budget impact, primarily driven by drug acquisition costs but partially offset by reduced cost of HF hospitalizations and CV deaths.
RCT Entities:
INTRODUCTION: In the USA, patients with chronic heart failure (HF) with reduced ejection fraction (HFrEF) following a worsening HF event (WHFE) have significantly increased healthcare resource use and medical costs. This analysis aimed to estimate the budget impact of vericiguat as an add-on therapy to guideline-directed medical therapy (GDMT) for the treatment of chronic HFrEF following a WHFE from a US commercial payer perspective. METHODS: A model was developed to estimate the budget impact of adding vericiguat to the formulary by comparing a current scenario (GDMT) and a new scenario (vericiguat plus GDMT) to a hypothetical 10-million-member commercial payer over a 3-year time horizon. Epidemiology data was obtained from literature. Treatment utilization rates of GDMT and clinical inputs (HF hospitalization and cardiovascular [CV] morality) were based on the VICTORIA trial in which patients with chronic HFrEF following a WHFE were randomized to GDMT plus placebo or GDMT plus vericiguat. Costs (2020 US$) included drug acquisition, hospitalization, routine care, and mortality. RESULTS: Approximately 20,510 prevalent cases in year 1 and 3109 annual incident cases in subsequent years were estimated to be eligible for treatment with vericiguat. At a utilization rate of 5%, 10%, and 15% for vericiguat over years 1-3, the per member per month (PMPM) budget impact was estimated to be $0.048, $0.064, and $0.086, respectively, associated with 44, 32, and 30 fewer HF hospitalizations and 7, 12, and 18 fewer CV deaths, respectively. Reduction in HF hospitalizations and CV deaths reduced the budget impact by 14% in total over 3 years. CONCLUSION: Adding vericiguat to commercial plan formulary was associated with limited budget impact, primarily driven by drug acquisition costs but partially offset by reduced cost of HF hospitalizations and CV deaths.
Authors: Kevin S Shah; Haolin Xu; Roland A Matsouaka; Deepak L Bhatt; Paul A Heidenreich; Adrian F Hernandez; Adam D Devore; Clyde W Yancy; Gregg C Fonarow Journal: J Am Coll Cardiol Date: 2017-11-12 Impact factor: 24.094
Authors: Ramachandran S Vasan; Vanessa Xanthakis; Asya Lyass; Charlotte Andersson; Connie Tsao; Susan Cheng; Jayashri Aragam; Emelia J Benjamin; Martin G Larson Journal: JACC Cardiovasc Imaging Date: 2017-10-05
Authors: Javed Butler; Mei Yang; Massimiliano Alfonzo Manzi; Gregory P Hess; Mahesh J Patel; Thomas Rhodes; Michael M Givertz Journal: J Am Coll Cardiol Date: 2019-03-05 Impact factor: 24.094
Authors: Jennifer E Ho; Asya Lyass; Douglas S Lee; Ramachandran S Vasan; William B Kannel; Martin G Larson; Daniel Levy Journal: Circ Heart Fail Date: 2012-12-27 Impact factor: 8.790
Authors: Jerry H Gurwitz; David J Magid; David H Smith; Robert J Goldberg; David D McManus; Larry A Allen; Jane S Saczynski; Micah L Thorp; Grace Hsu; Sue Hee Sung; Alan S Go Journal: Am J Med Date: 2013-03-14 Impact factor: 4.965
Authors: Adam P Bress; Jordan B King; Diana Brixner; Adrian Kielhorn; Harshali K Patel; Juan Maya; Vinson C Lee; Joseph Biskupiak; Mark Munger Journal: Pharmacotherapy Date: 2016-02-03 Impact factor: 4.705
Authors: Nasrien E Ibrahim; Yang Song; Christopher P Cannon; Gheorghe Doros; Patricia Russo; Angelo Ponirakis; Claire Alexanian; James L Januzzi Journal: ESC Heart Fail Date: 2019-07-03
Authors: Adam D DeVore; Bradley G Hammill; Puza P Sharma; Laura G Qualls; Robert J Mentz; Katherine Waltman Johnson; Gregg C Fonarow; Lesley H Curtis; Adrian F Hernandez Journal: J Am Heart Assoc Date: 2014-07-11 Impact factor: 5.501